Abstract
Objective and methods: Dupilumab, a human monoclonal antibody against the IL-4/13 receptor, has been used in Japan since 2018 for treatment of adult atopic dermatitis (AD) with inadequate response to existing therapies. We report the results of an interim analysis of ongoing post-marketing surveillance that evaluates long-term safety and effectiveness of dupilumab in real-world settings in Japan (UMIN Clinical Trial Registry No. UMIN000032807, data cut-off: March 2021).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
